Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry. 2023

Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
Division of Endocrinology and Metabolism, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.

The rapid emergence of SARS-CoV-2 variants of concern, the complexity of infection, and the functional redundancy of host factors, underscore an urgent need for broad-spectrum antivirals against the continuous COVID-19 pandemic, with drug repurposing as a viable therapeutic strategy. Here we report the potential of RNA G-quadruplex (RG4)-targeting therapeutic strategy for SARS-CoV-2 entry. Combining bioinformatics, biochemical and biophysical approaches, we characterize the existence of RG4s in several SARS-CoV-2 host factors. In silico screening followed by experimental validation identify Topotecan (TPT) and Berbamine (BBM), two clinical approved drugs, as RG4-stabilizing agents with repurposing potential for COVID-19. Both TPT and BBM can reduce the protein level of RG4-containing host factors, including ACE2, AXL, FURIN, and TMPRSS2. Intriguingly, TPT and BBM block SARS-CoV-2 pseudovirus entry into target cells in vitro and murine tissues in vivo. These findings emphasize the significance of RG4 in SARS-CoV-2 pathogenesis and provide a potential broad-spectrum antiviral strategy for COVID-19 prevention and treatment.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053586 Virus Internalization The entering of cells by viruses following VIRUS ATTACHMENT. This is achieved by ENDOCYTOSIS, by translocation of the whole virus across the cell membrane, by direct MEMBRANE FUSION of the viral membrane with the CELL MEMBRANE, or by fusion of the membrane of infected cells with the membrane of non-infected cells causing SYNCYTIA to be formed. Viral Entry,Viral Internalization,Viral Membrane Fusion,Virus Entry,Virus Membrane Fusion,Entry, Viral,Entry, Virus,Fusion, Viral Membrane,Internalization, Viral,Internalization, Virus,Membrane Fusion, Viral
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic
D064370 Spike Glycoprotein, Coronavirus A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion. Spike Glycoprotein, Bovine Coronavirus,Spike Glycoproteins, Coronavirus,E2 Spike Glycoprotein, Coronavirus,Glycoprotein S, Coronavirus,Spike Glycoprotein S1, Coronavirus,Spike Protein S2, Coronavirus,Spike Protein, Coronavirus,Coronavirus Spike Glycoprotein,Coronavirus Spike Protein

Related Publications

Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
January 2021, Angewandte Chemie (International ed. in English),
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
March 2021, Nature communications,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
July 2020, RSC advances,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
September 2020, Future medicinal chemistry,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
May 2023, Nature reviews. Drug discovery,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
October 2022, Chemical communications (Cambridge, England),
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
January 2024, Current research in structural biology,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
September 2021, Signal transduction and targeted therapy,
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
October 2021, Topics in current chemistry (Cham),
Qiyu Tong, and Geng Liu, and Xiongbo Sang, and Xinyue Zhu, and Xiaoli Fu, and Chao Dou, and Yue Jian, and Jiani Zhang, and Sailan Zou, and Guixiang Zhang, and Xiao Du, and Dan Liu, and Shiqian Qi, and Wei Cheng, and Yan Tian, and Xianghui Fu
January 2023, Chemical communications (Cambridge, England),
Copied contents to your clipboard!